TY - JOUR
T1 - Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment
AU - Banerjee, Aditya
AU - Ng, Jennifer
AU - Coleman, Jessica
AU - Ospina, Juan Pablo
AU - Mealy, Maureen
AU - Levy, Michael
N1 - Funding Information:
This study was funded by a grant from the National Institute of Allergy and Infectious Diseases , grant R01-AI130548 (ML) .
Publisher Copyright:
© 2018
PY - 2019/2
Y1 - 2019/2
N2 - Neuromyelitis optica spectrum disorder (NMOSD) attacks lead to incremental loss of function of the optic nerves and spinal cord. The standard of care for treatment of acute attacks to mitigate damage is high dose corticosteroids and, if needed, plasma exchange. Although the inclination among clinicians is to treat relapses as soon as they start, there is no previously published evidence to conclude that earlier treatment with corticosteroids is more effective in the long term. In this study, we correlated neurological outcomes from acute NMOSD relapses with delay to treatment, as well as demographic and clinical characteristics that influence prognosis.
AB - Neuromyelitis optica spectrum disorder (NMOSD) attacks lead to incremental loss of function of the optic nerves and spinal cord. The standard of care for treatment of acute attacks to mitigate damage is high dose corticosteroids and, if needed, plasma exchange. Although the inclination among clinicians is to treat relapses as soon as they start, there is no previously published evidence to conclude that earlier treatment with corticosteroids is more effective in the long term. In this study, we correlated neurological outcomes from acute NMOSD relapses with delay to treatment, as well as demographic and clinical characteristics that influence prognosis.
UR - http://www.scopus.com/inward/record.url?scp=85058209430&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058209430&partnerID=8YFLogxK
U2 - 10.1016/j.msard.2018.12.010
DO - 10.1016/j.msard.2018.12.010
M3 - Article
C2 - 30554039
AN - SCOPUS:85058209430
SN - 2211-0348
VL - 28
SP - 60
EP - 63
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
ER -